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Abstract. A pharmacoeconomic study of the rationality of the use of various chemotherapy regimens (“7 
+ 3” scheme) in the treatment of patients with acute forms of myeloid leukemia has been carried out. The 
use of the chemotherapy regimen “7 + 3” with 200 mg / m2 / per day dosage of cytarabine on 1-7 days 
allows to achieve a unit of treatment efficacy at a lower cost (CEA = 19.22 US $ / per unit of efficacy), 
compared with another dosage of cytarabine that was two times less, i.e., 100 mg / m² / day at the same 
period (CEA = US $ 20.18 / unit of effectiveness). The presented research results can be used in the 
formation of programs for the rational use of limited resources in the purchase of anticancer drugs for 
hematological cancer patients, as well as in the development of schemes for providing them with effective 
medical care in a hospital setting. 
1 Introduction 
According to the World Health Organization, leukemia 
occupies a leading position in the morbidity structure of 
the human lymphoid and hematopoietic systems [1-3].  
Specialists are particularly concerned about the fact that 
leukemias occupy the first positions in the structure of 
morbidity and mortality from malignant pathologies 
among people under the age of 17 years [4-6]. It is a well-
known fact, that this category of the population forms the 
socio-economic potential of any country, and the loss of 
patients under the age of 17 is an important demographic 
problem in any state and in society as a whole [7-8]. 
Therefore, the development of new approaches in the 
treatment of acute leukemia, in particular myeloid 
leukemia, is of both medical and socio-economic 
importance [9-10]. The basic principles of treatment of 
acute leukemia were formulated thanks to the 
achievements of American oncologists-hematologists (D. 
Pinkel, J. Simone, 1970, R. J. A. Aur, 1971), who in the 
last century successfully used in clinical practice the 
program of so-called "total therapy" in children [11-12]. 
The use of these programs in the pathogenetic and 
symptomatic treatment of patients with acute leukemia 
allowed further specialists of the St. Jude hospital (St. 
Jude Children's Research Hospital, Memphis, USA) in 
1979 to reach, and in the early 80-ies of the last century 
to cross the 50.0% threshold of survival of patients with 
acute forms of leukemia [13-15]. This was a significant 
achievement at that time in the development of 
Oncohematology. Acute leukemias from the category of 
fatal diseases of the human hematopoietic system 
gradually moved to the category of diseases that could be 
treated, and the percentage of 5-year survival rate of 
oncogematological patients has steadily increased with 
each decade. 
Modern principles of treatment of acute leukemia are 
based on the following basic principles: duration and 
intensity of therapy at all stages of development of 
malignant pathology; strict compliance with the doses of 
antitumor drugs, depending on the type of therapy and the 
timing of their use in accordance with the treatment 
protocols; the combination of cytostatic drugs in order to 
synchronize their mechanism of action with the main 
phases of the mitotic cycle of development of leukemic 
cells, namely, the appointment of drugs characterized by 
different phase cyclospecificity with drugs that differ in 
non-cyclical mechanism of action. This contributes to the 
maximum coverage of a significant number of leukemic 
cells; compliance with cyclical and precyclical use of 
antitumor drugs; timely elimination of side effects in the 
use of cytostatic drugs by prescribing a complex of 
antifungal and antimicrobial drugs [16-19]. In general, it 
should be noted that in the treatment of acute leukemia, a 
whole range of methods are used, namely chemotherapy, 
symptomatic, substitution, paliative, radiation therapy, as 
well as bone marrow transplantation. At the same time, 
the use of chemotherapy for a long time, as well as the 
relief of side effects of cytostatic drugs requires 
significant financial resources [10,11,18]. The limited 
nature of resources in the health care system may put 
forward the question on the process of achieving 
maximum therapeutic effect in the treatment of patients 
with acute leukemia, in particular myeloid leukemia. This 
problem can be solved by applying methods of 
pharmacoeconomical analysis, which has recently 
become increasingly important in various fields of 
practical medicine, including in Oncohematology [20]. 
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This statement allowed us to formulate the main goal of 
our research. 
2 Purpose of the study 
The objective of this study is the pharmacoeconomical 
research of the rationality of using various chemotherapy 
regimens ("7+3" scheme) in the treatment of patients with 
acute forms of myeloid leukemia. 
3 Materials and methods  
In the study, we used the method of cost-effectiveness 
analysis (CEA). We calculated the value of the CEA 
indicator and the incremental cost – effectiveness ratio 
(ICER), which expresses the value of the additional 
amount that have to be spent to achieve an additional 
unit of effectiveness when using a more effective and 
more costly treatment method instead of another. To 
assess the rationality of using certain doses of anticancer 
drugs from the group of antimetabolics and 
anthracycline antibiotics, we used the data of multicenter 
randomized studies of chemotherapy of myeloid acute 
leukemia, which had been carried out by Russian 
scientists [13]. The purpose of these studies was to 
analyze the effectiveness of the use of the so-called 
"large" and "small" doses of antimetabolites (cytarabine 
drug) to achieve stable induction / consolidation in the 
first line of chemotherapy for acute forms of myeloid 
leukemia. There were analysed 145 oncohematological 
patients of 18 hematological centers from 15 cities of the 
Russian Federation for 1.5 years in this study. Two 
groups of patients were prescribed two courses of 
chemotherapy "7 + 3" using high doses of daunorubicin, 
60 mg / m2 per injection against the background of 
continuous infusion of cytarabine on the 2nd course of 
treatment at a dose of 100 and 200 mg / m2 / day on the 
1-7th day. The total interval between courses of 
chemotherapy depended on the degree of cytopenia and 
averaged about 10-15 days. 
In our pharmacoeconomic studies, as a unit of 
effectiveness, we took the indicators of achieving 
complete remission in patients (%) while using the 
remission induction regimens after chemotherapy from 
the abovementioned studies [13] The basic data is shown 
in Table I. As one can see, the first group of patients 
used cytarabine preparations at a dose of 100 mg / m², 
and the second, respectively, at a dose of 200 mg / m² 
per day on the 1st-7th day, that is, twice more than first 
group. We calculated the total medical (direct and 
indirect) costs associated with the use of chemotherapy 
regimens for the specified group of oncohematological 
patients. To calculate the cost of the average daily dose 
of anticancer drugs, we calculated the values of the 
patient's body area (m2), which corresponded to a person 
with a body weight of 70 kg. In our calculations, we 
used the data of those trade names of anticancer drugs 
under the international non-proprietary names that had 
the lowest price characteristics. 
All calculations had been carried out first in the 
Ukrainian national currency (UAH), and then they were 
converted into US $ at the rate of the National Bank of 
Ukraine as of 01.01.2020 (1 US dollar = 23.68 UAH). 
Table 1. Schemes of chemotherapy for acute forms of 
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Daunorubicin 60 mg 
mg / m² per day (1-3 
days) 
Daunorubicin lyophil. 
powder for inj. 20 mg 




powder for inj. sol.  
100 mg (fl.), with 
solvent in amp. 5 ml, 
No. 1, "Pfizer Italia" 
(Italy). 
Cytarabine - 100 mg / 




period - 1.5 
years) 
Daunorubicin 60 mg 
mg / m² per day (1-3 
days) 
Cytarabine - 200 mg / 
m² / day (1-7 days) 
In addition to the methods of pharmacoeconomic 
research, we also used general scientific (historical, 
logical, graphic, comparative, structural, etc.) and 
mathematical and statistical methods of analysis and 
scientific research. The statistical data processing had 
been carried out using the statistical package StatSoft. 
Inc. (2014), Statistica version 12.7 (May 2015) and 
Excel spreadsheet. After a preliminary assessment of the 
data, all indicators were imported into a Statistica 6.0 
standard program for the applied statistical analysis. A p-
value <0.05 was considered statistically significant. 
4 Results and discussion  
As a result of pharmacoeconomical research, we 
determined the value of the ratio of total medical 
expenses when using remission induction schemes of the 
first line of chemotherapy to the effectiveness of its use in 
two groups of patients with acute myeloid leukemia. The 
results of the research are reflected in Table 2. 
In the first group of patients, the indicator of total 
medical expenses was US $ 831.48, and in the second 
group-US $ 1278.28. Thus, the use of the "7+3" scheme 
in patients with acute myeloid leukemia in a higher 
dosage of citarabine was 1.5 times more expensive than 
when using this scheme in the group of patients #1. At 
the same time, the indicator of clinical effectiveness in 
the second group of hematological patients was 1.6 times 
higher than in the case of using citarabine at a dose of 
100 mg/m2 /day on day 1-7. 
Thus, when calculating the CEA index in the first 
group of patients, the result was 20.18 US $/per unit of 
clinical effectiveness (achieving complete remission in 
patients, in%), which is 5.0% more than when using the 
"7+3" scheme with a higher (200 mg/m2/day on day 1-7) 
dosage of citarabine drugs. Thus, among the 
chemotherapy schemes there were no dominant methods 
in the organization of the treatment process. Then we 
calculated the value of the ICER indicator. The value of 
the ICER indicator was 418.19 UAH / per unit of 
effectiveness or ICER=17.66 US $/per unit of 
chemotherapy effectiveness. As we can see, despite the 
fact that the second group of patients used the "7+3" 
chemotherapeutic scheme, which contained citarabine at 
a dose that was twice higher than in the first group of 
patients, its use demonstrated higher indicators. That’s 
why chemotherapeutic regimen used in second group is 
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more effective from the position of rational use of 
resources. 
Table 2. Results of pharmacoeconomical analysis "7+3" in 
chemotherapy of patients with acute myeloid leukemia ("Cost-
Effectiveness" Method”) 
Data on the effectiveness of different chemotherapy 




















Group of patients #1: (scheme N1): daunorubicin 60 mg 
mg/m2 per day on the 1st-3rd day; citarabin – 100 
mg/m2/day on the 1st-7th day. 
41,2 19689,45 831,48 477,86 20,18 
Group of patients #2 (scheme N2): daunorubicin 60 mg 
mg/m2 per day on the 1st-3rd day; citarabin-200 mg/m2/day 
on 1st-7th day. 
66,5 30269,67 1278,28 455,13 19,22 
At the same time, it should be noted that the use of 
the "7+3" chemotherapy regimen in the dosage of 
citarabine 200 mg/m2/day on day 1st-7th requires more 
careful supervision over the development of side effects 
from the use of antitumor drugs in patients with acute 
myeloid leukemia [6,8,13]. In the case of severe 
cytopenia and fungal infections, the effectiveness of 
chemotherapy may be significantly lower than in the 
group of patients receiving chemotherapy with cytarabine 
at a dosage of 100 mg / m2 / day on day 1st-7th.  
5 Conclusion 
Stating the results of pharmacoeconomical studies of 
the use of two chemotherapy regimens (scheme "7+3") 
for acute myeloid leukemia using different dosages of 
citarabine, we can claim the following. Using a 
chemotherapy regimen ("7+3") with a dosage of 
citarabine 200 mg / m2 / day on day 1st-7th in the second 
group of patients allows to achieve a unit of treatment 
effectiveness at a lower cost, compared to the group of 
patients who treated with citarabine at a dosage that was 
twice less (100 mg/m2/day on day 1-7). In the future, the 
presented research results can be used in the formation of 
programs for the rational use of limited health care 
resources in the purchase of anti-cancer drugs for 
oncohematological patients, as well as in the 
development of schemes for providing effective medical 
care to these groups of cancer patients. There is no doubt 
that the results of pharmacoeconomical studies of the 
rationality of using various chemotherapy regimens 
should be of priority importance in the implementation of 
the above measures. 
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